18
Participants
Start Date
May 31, 2014
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
Anagrelide CR
Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
Gettysburg Cancer Center, Hillsdale
Wake Forest Baptist Health, Winston-Salem
Innovative Medical Research of South Florida, Inc., Aventura
Cancer Center of Kansas, Wichita
The University of Texas MD Anderson Cancer Center, Houston
Cancer Care Centers of South Texas, New Braunfels
Cancer Care Centers of South Texas, San Antonio
East Valley Hematology and Oncology Medical Group, Burbank
California Cancer Associates for Research & Excellence (cCARE), Encinitas
California Cancer Associates for Research & Excellence (cCARE), Escondido
California Cancer Associates For Research and Excellence, Fresno
Lead Sponsor
Galena Biopharma, Inc.
INDUSTRY